Vaccine Therapy in Treating Patients With Kidney Cancer
Injection of Renal Cell Carcinoma Patients With Human and Mouse Prostate Specific Membrane Antigen (PSMA) DNA: A Phase I Trial to Assess Safety and Immune Response
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.
연구 개요
상태
정황
상세 설명
OBJECTIVES:
Primary
- Determine the safety and feasibility of vaccination with human and mouse prostate-specific membrane antigen (PSMA) DNA in patients with renal cell carcinoma.
- Determine the maximum tolerated dose of this regimen in these patients.
- Determine antibody responses to human PSMA in patients treated with this regimen.
Secondary
- Assess antitumor response in patients treated with this regimen.
OUTLINE: This is a randomized, dose-escalation study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive human prostate-specific membrane antigen (PSMA) DNA vaccine intramuscularly (IM) once every 3 weeks for 3 doses (doses 1-3). Patients then receive mouse PSMA DNA vaccine IM once every 3 weeks for 3 doses (doses 4-6).
- Arm II: Patients receive mouse PSMA DNA vaccine IM once every 3 weeks for 3 doses (doses 1-3). Patients then receive human PSMA DNA vaccine IM once every 3 weeks for 3 doses (doses 4-6).
In both arms, treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive additional booster vaccinations with the second form of PSMA DNA vaccine received (for doses 4-6) every 8 weeks for up to 4 additional doses.
Cohorts of 3-6 patients per arm receive escalating doses of human and mouse PSMA DNA vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
Patients are followed every 3 months for 2 years.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
New York
-
New York, New York, 미국, 10021
- Memorial Sloan Kettering Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
- Histologically confirmed renal cell carcinoma
Patients with minimal disease burden are eligible provided they meet one or more of the following criteria:
- Prior nephrectomy and completely resected metastases
Favorable-risk group, as defined by all of the following criteria:
- Karnofsky 80-100%
- Hemoglobin ≥ 13 g/dL (male) or ≥ 12 g/dL (female)
- Corrected calcium ≤ 10 mg/dL
- Prior nephrectomy
- Serum lactate dehydrogenase ≤ 200 μ/L
- Prior nephrectomy with metastases confined to lung and/or small volume metastatic disease (< 3 cm) exclusive of bone and liver
- No spinal, epidural, or CNS lesions
- No bone, liver or brain disease
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- See Disease Characteristics
- Karnofsky 80-100%
Life expectancy
- Not specified
Hematopoietic
- See Disease Characteristics
- WBC ≥ 3,500/mm^3
- Hemoglobin ≥ 12.0 g/dL
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin < 2.0 mg/dL
- SGOT < 3.0 times upper limit of normal
Renal
- See Disease Characteristics
- Creatinine ≤ 2.0 mg/dL OR
- Creatinine clearance ≥ 40 mL/min
Cardiovascular
- No clinically significant cardiac disease
- No New York Heart Association class III or IV heart disease
Pulmonary
- No severe debilitating pulmonary disease
Other
- Fertile patients must use effective contraception
- No other active secondary malignancy within the past 5 years except non-melanoma skin cancer
- No infection requiring antibiotic treatment
- No narcotic- or steroid-dependent pain
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- At least 4 weeks since prior chemotherapy
Endocrine therapy
- At least 4 weeks since prior corticosteroid therapy
Radiotherapy
- At least 4 weeks since prior radiotherapy
- No concurrent radiotherapy to only measurable lesion
Surgery
- See Disease Characteristics
- No concurrent surgery
Other
- Recovered from all prior therapy
- No other concurrent anticancer therapy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: human PSMA
Patients will receive a total of 6 vaccinations via the intramuscular route.
Sites of injection should have intact lymphatic drainage.
Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
|
|
|
실험적: mouse PSMA
Patients will receive a total of 6 vaccinations via the intramuscular route.
Sites of injection should have intact lymphatic drainage.
Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
안전
기간: 2 년
|
2 년
|
|
feasibility
기간: 2 years
|
2 years
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
antibody responses
기간: 2 years
|
2 years
|
|
anti-tumor response
기간: 2 years
|
2 years
|
공동 작업자 및 조사자
수사관
- 연구 의자: Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .